CoMFA and CoMSIA on the inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with N-(4-oxo-1(4H)-naphthalenylidene) benzenesulfonamide derivatives

Bulletin of the Korean Chemical Society

Volumn 26, Issue 12, 2005, Pages 1941-1945

  Myung, Pyung Keun ^a   Park, Kyung Yong ^a   Sung, Nack Do ^a  

^a Chungnam National University   (South Korea)

Author keywords

Calcineurin NFAT signaling; CoMFA CoMSIA model; Immunomodulatory agent; N (4 Oxo 1(4H) naphthalenylidene)benzenesulfonamides

Indexed keywords

BENZENE; CARBONYLATION; ELECTRIC FIELDS; MATHEMATICAL MODELS; OXYGEN;

CALCINEURIN-NFAT SIGNALING; COMFA & COMSIA MODEL; IMMUNOMODULATORY AGENT;

PROTEINS;

EID: 31744441356     PISSN: 02532964     EISSN: 12295949     Source Type: Journal    
DOI: 10.5012/bkcs.2005.26.12.1941     Document Type: Article

References (26)

1. (a) Thomson, A. W. In Therapeutic Immunosuppression; Kluwer Academic Publishers: 2001; p 130.
2. (b) Bohlin, L. Phytochem. Rev. 1995, 37, 137.
3. Pawson, T.; Scott, J. D. Science 1997, 278, 2075.
4. Shaw, K. T.; Ho, A. M.; Raghavan, A.; Kim, J.; Jain, J.; Park, J.; Sharma, S.; Rao, A.; Hogan, P. G. Proc. Natl. Acad. Sci., USA 1995, 92, 11205.
5. Beals, C. R.; Clipstone, N. A.; Ho, S. N.; Crabtree, G. R. Genes. Dev. 1997, 11, 824.
6. Aramburu, J.; Garcia-Cozar, F.; Raghavan, A.; Okamura, H.; Rao, A.; Hogan, P. G. Mol. Cell. 1998, 1, 627.
7. Aramburu, J.; Yaffe, M. B.; López-Rodríguez, C.; Cantley, L. C.; Hogan, P. G.; Rao, A. Science 1999, 285, 2129.
8. Roehrl, M. H.; Kang, S.; Aramburu, J.; Wagner, G.; Rao, A.; Hogan, P. G. Proc. Natl. Acad. Sci. USA 2004, 101, 7544.
9. Kubinyi, H., In 3D-QSAR in Drug Design; Theory, Methods and Applications; Escom: Leiden, 1993.
10. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988, 110, 5959.
11. (a) Klebe, G. Prospect Drug Discovery Des. 1998, 12, 87.
12. (b) Klebe, G.; Abraham, U. J. Comput. Aid. Mol. Des. 1999, 13, 1.
13. (c) Bohm, M.; Sturzebecher, J.; Klebe, G. J. Med. Chem. 1999, 42, 458.
14. Tripos Associates, Inc., 1699 S. Hanley Road, Suite 303, St. Louis, MO., 63144-2913 U.S.A., http://www.tripos.com/Bookshelf/qsar/.
15. Kerr, R. Biophys. J. 1964, 67, 1501.
16. Purcell, W. P.; Singer, J. A. J. Chem. Eng. Data. 1967, 12, 235.
17. Klebe, G. In 3D QSAR Drug Design, Theory, Methods and Applications: Structural Alignment of Molecules; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 173-199.
18. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. In Computer-Assisted Drug Design: The Conformational Parameter in Drug Design; Active Analog Approach; Olsen, E. C.; Christoffersen, R. E., Eds.; American Chemical Society: Washington, D. C. 1979; pp 205-226.
19. Raichurkar, A. V.; Kulkarni, V. M. J. Med. Chem. 2003, 46, 4419.
20. 2=dichloro substituent, 5 is excluded, because the 4-oxo-1(4H)-naphthalenylidene part is not aligned. In the case of template B, on the other hand, though all the 13 compounds are aligned, the models of the compounds are derived with the 8 and 12 excluded. In the case of template C, the models are derived based on the subjects of all compounds that exclude the 4 and 12, as well as the 5.
21. (a) Stahle, L.; Wold, S. Prog. Med. Chem. 1988, 25, 291.
22. (b) Geladi, P. J. Chemon. 1998, 2, 231.
23. Cramer, R. D., III.; Bunce, J. D.; Patterson, D. E. Quant. Struct. Act. Relat. 1988, 7, 18.
24. 2).
25. (a) Hansch, C.; Steward, A. R. J. Med. Chem. 1964, 7, 691.
26. (b) Fujita, T. In Progress in Physical Organic Chemistry; Taft, R., Ed.; Wiely & Sons: 1983; Vol. 14, pp 75-113.